Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...

Nuclera and leadXpro have formed a partnership to accelerate structure-based drug design targeting complex membrane proteins, ...

When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Subscribe to our newsletter for the latest ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

A next-generation cryo-TEM enhances structural biology by improving imaging clarity, and accessibility. AI-driven workflows ...

For many people, "protein" is the key element of a food order. However, beyond the preferred choice of meats or plant-based alternatives, proteins encompass a large class of complex biomolecules whose ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...

CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...

Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...